Down-regulation of p38 mitogen-activated protein kinase activation and proinflammatory cytokine production by mitogen-activated protein kinase inhibitors in inflammatory bowel disease

Clinical and Experimental Immunology

Volumn 162, Issue 1, 2010, Pages 108-115

  Docena, G ^a   Rovedatti, L ^c   Kruidenier, L ^b   Fanning, A ^d   Leakey, N A B ^a   Knowles, C H ^a   Lee, K ^b   Shanahan, F ^d   Nally, K ^d   McLean, P G ^b   Di Sabatino, A ^c   MacDonald, T T ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c UNIVERSITY OF PAVIA   (Italy)

^d UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Crohn's disease; lamina propria mononuclear cell; p38 inhibitor; TNF ; ulcerative colitis

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; ARTICLE; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOWN REGULATION; DRUG ACTIVITY; ENTERITIS; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTESTINE BIOPSY; LAMINA PROPRIA; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; ULCERATIVE COLITIS; UPREGULATION;

ADOLESCENT; ADULT; BLOTTING, WESTERN; CELLS, CULTURED; CYTOKINES; DOWN-REGULATION; ENZYME ACTIVATION; ENZYME INHIBITORS; FEMALE; HUMANS; IMIDAZOLES; INFLAMMATION MEDIATORS; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-1BETA; INTERLEUKIN-6; INTESTINAL MUCOSA; MALE; MIDDLE AGED; NIACINAMIDE; ORGAN CULTURE TECHNIQUES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PYRIDINES; PYRIMIDINES; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 77956497996     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2010.04203.x     Document Type: Article

References (39)

1. Papadakis KA, Targan SR. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med 2000 51 : 289 298.
2. van Deventer SJ. Review article: targeting TNF alpha as a key cytokine in the inflammatory processes of Crohn's disease-the mechanisms of action of infliximab. Aliment Pharmacol Ther 1999 13 : 3 8.
3. Minden A, Lin A, McMahon M et al. Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 and MEKK. Science 1994 266 : 1719 1723.
4. Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 2001 81 : 807 869.
5. Ono K, Han J. The p38 signal transduction pathway: activation and function. Cell Signal 2000 12 : 1 13.
6. Cook R, Wu CC, Kang YJ, Han J. The role of the p38 pathway in adaptive immunity. Cell Mol Immunol 2007 4 : 253 259.
7. Wang XS, Diener K, Manthey CL et al. Molecular cloning and characterization of a novel p38 mitogen-activated protein kinase. J Biol Chem 1997 272 : 23668 23674.
8. Ulfgren AK, Andersson U, Engström M et al. Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis. Arthritis Rheum 2000 43 : 2391 2396.
9. Waetzig GH, Seegert D, Rosenstiel P et al. p38 mitogen-activated protein kinase is activated and linked to TNF-alpha signaling in inflammatory bowel disease. J Immunol 2002 168 : 5342 5351.
10. Hommes D, van den Blink B, Plasse T et al. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology 2002 122 : 7 14.
11. Malamut G, Cabane C, Dubuquoy L et al. No evidence for an involvement of the p38 and JNK mitogen-activated protein in inflammatory bowel diseases. Dig Dis Sci 2006 51 : 1443 1453.
12. ten Hove T, van den Blink B, Pronk I et al. Dichotomal role of inhibition of p38 MAPK with SB 203580 in experimental colitis. Gut 2002 50 : 507 512.
13. Branger J, van den Blink B, Weijer S et al. Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. J Immunol 2002 168 : 4070 4077.
14. Di Sabatino A, Pender SL, Jackson CL et al. Functional modulation of Crohn's disease myofibroblasts by anti-tumor necrosis factor antibodies. Gastroenterology 2007 133 : 137 149.
15. Cuenda A, Rouse J, Doza Y et al. SB 203580 is a specific inhibitor of a MAP kinase homolog which is stimulated by cellular stresses and interleukin-1. FEBS Letters 1995 364 : 229 233.
16. Boehm JC, Widdowson K, Callahan J, Wan Z. Preparation of 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-ones as CSBP/p38 kinase inhibitors. PCT Int Appl 2003 68 : WO 2003088972.
17. Aston N, Bamborough P, Walker A. Preparation of nicotinamides as p38 inhibitors. PCT Int Appl 2003 75 : WO 2003068747.
18. Neurath MF, Fuss I, Kelsall BL et al. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 1995 182 : 1281 1290.
19. Monteleone G, Biancone L, Marasco R et al. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology 1997 112 : 1169 1178.
20. Fuss IJ, Neurath M, Boirivant M et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 1996 157 : 1261 1270.
21. Heller F, Florian P, Bojarski C et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 2005 129 : 550 564.
22. Heller F, Fuss IJ, Nieuwenhuis EE et al. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity 2002 17 : 629 638.
23. Seegert D, Rosenstiel P, Pfahler H et al. Increased expression of IL-16 in inflammatory bowel disease. Gut 2001 48 : 326 332.
24. Maerten P, Shen C, Colpaert S et al. Involvement of interleukin 18 in Crohn's disease: evidence from in vitro analysis of human gut inflammatory cells and from experimental colitis models. Clin Exp Immunol 2004 135 : 310 317.
25. Nishiwaki T, Ina K, Goto H et al. Possible involvement of the interleukin-15 and interleukin-15 receptor system in a heightened state of lamina propria B cell activation and differentiation in patients with inflammatory bowel disease. J Gastroenterol 2005 40 : 128 136.
26. Dinarello CA, Kim SH. IL-32, a novel cytokine with a possible role in disease. Ann Rheum Dis 2006 65 : 61 4.
27. Seiderer J, Elben I, Diegelmann J et al. Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): upregulated colonic IL-17F expression in active Crohn's disease and analysis of the IL17F p.His161Arg polymorphism in IBD. Inflamm Bowel Dis 2008 14 : 437 445.
28. Reinecker HC, Steffen M, Witthoeft T et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6 and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993 94 : 174 181.
29. Brandt E, Colombel JF, Ectors N et al. Enhanced production of IL-8 in chronic but not in early ileal lesions of Crohn's disease (CD). Clin Exp Immunol 2000 122 : 180 185.
30. Becker C, Wirtz S, Blessing M et al. Constitutive p40 promoter activation and IL-23 production in the terminal ileum mediated by dendritic cells. J Clin Invest 2003 112 : 693 706.
31. Langrish CL, Chen Y, Blumenschein WM et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005 201 : 233 240.
32. Hollenbach E, Neumann M, Vieth M et al. Inhibition of p38 MAP kinase- and RICK/NF-kappaB-signaling suppresses inflammatory bowel disease. FASEB J 2004 18 : 1550 1552.
33. Badger AM, Bradbeer JN, Votta B et al. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J Pharmacol Exp Ther 1996 279 : 1453 1461.
34. Waetzig GH, Seegert D, Rosenstiel P et al. p38 mitogen-activated protein kinase is activated and linked to TNF-alpha signaling in inflammatory bowel disease. J Immunol 2002 168 : 5342 5351.
35. Waetzig GH, Rosenstiel P, Nikolaus S et al. Differential p38 mitogen-activated protein kinase target phosphorylation in responders and nonresponders to infliximab. Gastroenterology 2003 125 : 633 634.
36. Schreiber S, Feagan B, D'Haens G et al., BIRB796 Study Group. Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006 4 : 325 334.
37. Scaldaferri F, Sans M, Vetrano S et al. The role of MAPK in governing lymphocyte adhesion to and migration across the microvasculature in inflammatory bowel disease. Eur J Immunol 2009 39 : 290 300.
38. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index: National Cooperative Crohn's Disease Study. Gastroenterology 1976 70 : 439 444.
39. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomized study. BMJ 1989 298 : 82 6.